ÂÜÀòÂÒÂ×

Xiao Ting Sun has a diverse work experience starting from the role of Associate at Mercer Management Consulting in 2010. From 2011 to 2012, Sun worked as a Director at a company called "»ÔÈð." Sun then joined Sunovion Pharmaceuticals in 2012 as a Senior Director, where they were responsible for leading and managing the Lunesta and Xopenex franchises. In 2014, Sun became the Director of Business Development at the University of Michigan Medical School. From 2016 to 2018, Sun served as the Founding Managing Director of Fast Forward Medical Innovation at Michigan Medicine, during which they formed and built a team to drive commercialization and entrepreneurial activities. From 2018 to 2020, Sun took on multiple roles at Milendo Therapeutics, including Vice President Corporate Affairs and Vice President Business Operations. Currently, Sun holds the role of Chief Operating Officer at ONL Therapeutics, which started in 2020.

Xiao Ting Sun pursued a Bachelor of Arts degree in Psychobiology from Harvard University from 2003 to 2007. Subsequently, they attended Harvard Business School from 2008 to 2009 to obtain a Master of Business Administration (MBA) degree, specializing in Business Administration and Management.